S&P 500   4,577.10 (+1.42%)
DOW   34,639.79 (+1.82%)
QQQ   389.91 (+0.72%)
AAPL   163.76 (-0.61%)
MSFT   329.49 (-0.18%)
FB   310.39 (-0.07%)
GOOGL   2,859.32 (+1.36%)
AMZN   3,437.36 (-0.18%)
TSLA   1,084.60 (-0.95%)
NVDA   321.26 (+2.20%)
BABA   122.00 (-0.40%)
NIO   36.20 (-5.51%)
CGC   10.36 (+4.23%)
AMD   150.68 (+1.05%)
GE   95.23 (+2.40%)
MU   82.88 (-2.67%)
T   23.05 (+3.69%)
F   19.87 (+1.48%)
DIS   147.20 (+3.55%)
PFE   53.04 (-3.00%)
AMC   30.28 (+5.99%)
ACB   6.14 (+2.16%)
BA   202.38 (+7.54%)
S&P 500   4,577.10 (+1.42%)
DOW   34,639.79 (+1.82%)
QQQ   389.91 (+0.72%)
AAPL   163.76 (-0.61%)
MSFT   329.49 (-0.18%)
FB   310.39 (-0.07%)
GOOGL   2,859.32 (+1.36%)
AMZN   3,437.36 (-0.18%)
TSLA   1,084.60 (-0.95%)
NVDA   321.26 (+2.20%)
BABA   122.00 (-0.40%)
NIO   36.20 (-5.51%)
CGC   10.36 (+4.23%)
AMD   150.68 (+1.05%)
GE   95.23 (+2.40%)
MU   82.88 (-2.67%)
T   23.05 (+3.69%)
F   19.87 (+1.48%)
DIS   147.20 (+3.55%)
PFE   53.04 (-3.00%)
AMC   30.28 (+5.99%)
ACB   6.14 (+2.16%)
BA   202.38 (+7.54%)
S&P 500   4,577.10 (+1.42%)
DOW   34,639.79 (+1.82%)
QQQ   389.91 (+0.72%)
AAPL   163.76 (-0.61%)
MSFT   329.49 (-0.18%)
FB   310.39 (-0.07%)
GOOGL   2,859.32 (+1.36%)
AMZN   3,437.36 (-0.18%)
TSLA   1,084.60 (-0.95%)
NVDA   321.26 (+2.20%)
BABA   122.00 (-0.40%)
NIO   36.20 (-5.51%)
CGC   10.36 (+4.23%)
AMD   150.68 (+1.05%)
GE   95.23 (+2.40%)
MU   82.88 (-2.67%)
T   23.05 (+3.69%)
F   19.87 (+1.48%)
DIS   147.20 (+3.55%)
PFE   53.04 (-3.00%)
AMC   30.28 (+5.99%)
ACB   6.14 (+2.16%)
BA   202.38 (+7.54%)
S&P 500   4,577.10 (+1.42%)
DOW   34,639.79 (+1.82%)
QQQ   389.91 (+0.72%)
AAPL   163.76 (-0.61%)
MSFT   329.49 (-0.18%)
FB   310.39 (-0.07%)
GOOGL   2,859.32 (+1.36%)
AMZN   3,437.36 (-0.18%)
TSLA   1,084.60 (-0.95%)
NVDA   321.26 (+2.20%)
BABA   122.00 (-0.40%)
NIO   36.20 (-5.51%)
CGC   10.36 (+4.23%)
AMD   150.68 (+1.05%)
GE   95.23 (+2.40%)
MU   82.88 (-2.67%)
T   23.05 (+3.69%)
F   19.87 (+1.48%)
DIS   147.20 (+3.55%)
PFE   53.04 (-3.00%)
AMC   30.28 (+5.99%)
ACB   6.14 (+2.16%)
BA   202.38 (+7.54%)
NASDAQ:ALKS

Alkermes Stock Forecast, Price & News

$22.11
+0.64 (+2.98%)
(As of 12/2/2021 12:00 AM ET)
Add
Compare
Today's Range
$21.34
$22.12
50-Day Range
$21.47
$32.13
52-Week Range
$18.02
$33.00
Volume
1.05 million shs
Average Volume
1.54 million shs
Market Capitalization
$3.58 billion
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.95
30 days | 90 days | 365 days | Advanced Chart
Receive ALKS News and Ratings via Email

Sign-up to receive the latest news and ratings for Alkermes and its competitors with MarketBeat's FREE daily newsletter.


Alkermes logo

About Alkermes

Alkermes Plc is a biopharmaceutical company, which engages in the development, research, and commercialization of medicines that are designed to address unmet medical needs of patients in major therapeutic areas. Its products include Aristada, which is used for the treatment of schizophrenia in adults; and Vivitrol, which is an injectable medication for the treatment of alcohol dependence and for the prevention of relapse to opioid dependence, following opioid detoxification. The company was founded on May 4, 2011 and is headquartered in Dublin, Ireland.

Headlines

Alkermes in Action: Giving Tuesday - Yahoo Finance
December 2, 2021 |  finance.yahoo.com
Alkermes (NASDAQ:ALKS) Now Covered by Analysts at Citigroup
December 1, 2021 |  americanbankingnews.com
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:ALKS
CUSIP
G0176710
Employees
2,245
Year Founded
1987

Sales & Book Value

Annual Sales
$1.04 billion
Cash Flow
$0.37 per share
Book Value
$6.70 per share

Profitability

Net Income
$-110.86 million
Pretax Margin
-7.19%

Debt

Price-To-Earnings

Miscellaneous

Free Float
154,218,000
Market Cap
$3.58 billion
Optionable
Optionable

Company Calendar

Last Earnings
10/26/2021
Today
12/02/2021
Fiscal Year End
12/31/2021
Next Earnings (Estimated)
2/10/2022

Social Links


MarketRank

Overall MarketRank

2.09 out of 5 stars

Medical Sector

511th out of 1,391 stocks

Pharmaceutical Preparations Industry

236th out of 669 stocks

Analyst Opinion: 4.0Community Rank: 4.8Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -












Alkermes (NASDAQ:ALKS) Frequently Asked Questions

Is Alkermes a buy right now?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alkermes in the last twelve months. There are currently 1 sell rating, 5 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" Alkermes stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ALKS, but not buy additional shares or sell existing shares.
View analyst ratings for Alkermes
or view top-rated stocks.

How has Alkermes' stock been impacted by Coronavirus?

Alkermes' stock was trading at $16.25 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, ALKS shares have increased by 36.1% and is now trading at $22.11.
View which stocks have been most impacted by COVID-19
.

When is Alkermes' next earnings date?

Alkermes is scheduled to release its next quarterly earnings announcement on Thursday, February 10th 2022.
View our earnings forecast for Alkermes
.

How were Alkermes' earnings last quarter?

Alkermes plc (NASDAQ:ALKS) issued its quarterly earnings results on Tuesday, October, 26th. The company reported $0.14 earnings per share for the quarter, beating the Zacks' consensus estimate of $0.06 by $0.08. The firm had revenue of $294.10 million for the quarter, compared to analysts' expectations of $302.93 million. Alkermes had a positive trailing twelve-month return on equity of 1.26% and a negative net margin of 8.12%. The company's quarterly revenue was up 11.0% on a year-over-year basis. During the same period in the previous year, the business earned $0.12 earnings per share.
View Alkermes' earnings history
.

What guidance has Alkermes issued on next quarter's earnings?

Alkermes updated its FY 2021 earnings guidance on Wednesday, November, 3rd. The company provided earnings per share guidance of $0.520-$0.700 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $0.620. The company issued revenue guidance of $1.15 billion-$1.19 billion, compared to the consensus revenue estimate of $1.17 billion.

What price target have analysts set for ALKS?

7 brokers have issued 1-year price objectives for Alkermes' shares. Their forecasts range from $22.00 to $36.00. On average, they anticipate Alkermes' share price to reach $28.71 in the next year. This suggests a possible upside of 29.9% from the stock's current price.
View analysts' price targets for Alkermes
or view top-rated stocks among Wall Street analysts.

Who are Alkermes' key executives?

Alkermes' management team includes the following people:

What is Richard F. Pops' approval rating as Alkermes' CEO?

119 employees have rated Alkermes CEO Richard F. Pops on Glassdoor.com. Richard F. Pops has an approval rating of 84% among Alkermes' employees.

What other stocks do shareholders of Alkermes own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Alkermes investors own include Gilead Sciences (GILD), Netflix (NFLX), Pfizer (PFE), NVIDIA (NVDA), AbbVie (ABBV), Starbucks (SBUX), (CELG), Intel (INTC), Johnson & Johnson (JNJ) and Tesla (TSLA).

What is Alkermes' stock symbol?

Alkermes trades on the NASDAQ under the ticker symbol "ALKS."

Who are Alkermes' major shareholders?

Alkermes' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Sarissa Capital Management LP (8.17%), BlackRock Inc. (8.09%), Wellington Management Group LLP (7.30%), Primecap Management Co. CA (3.96%), Renaissance Technologies LLC (2.93%) and Hardman Johnston Global Advisors LLC (2.62%). Company insiders that own Alkermes stock include Craig C Hopkinson, David Joseph Gaffin, David W Anstice, Emily Peterson Alva, Iain Michael Brown, Michael J Landine, Nancy Wysenski, Richard F Pops and Wendy L Dixon.
View institutional ownership trends for Alkermes
.

Which major investors are selling Alkermes stock?

ALKS stock was sold by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, Camber Capital Management LP, Millennium Management LLC, Renaissance Technologies LLC, Credit Suisse AG, Morgan Stanley, Invesco Ltd., and UBS Group AG. Company insiders that have sold Alkermes company stock in the last year include Craig C Hopkinson, David Joseph Gaffin, David W Anstice, Iain Michael Brown, Michael J Landine, Richard F Pops, and Wendy L Dixon.
View insider buying and selling activity for Alkermes
or view top insider-selling stocks.

Which major investors are buying Alkermes stock?

ALKS stock was bought by a variety of institutional investors in the last quarter, including Hardman Johnston Global Advisors LLC, Sarissa Capital Management LP, Two Sigma Advisers LP, Dimensional Fund Advisors LP, California Public Employees Retirement System, Balyasny Asset Management LLC, Balyasny Asset Management LLC, and Victory Capital Management Inc.. Company insiders that have bought Alkermes stock in the last two years include Emily Peterson Alva, and Nancy Wysenski.
View insider buying and selling activity for Alkermes
or or view top insider-buying stocks.

How do I buy shares of Alkermes?

Shares of ALKS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Alkermes' stock price today?

One share of ALKS stock can currently be purchased for approximately $22.11.

How much money does Alkermes make?

Alkermes has a market capitalization of $3.58 billion and generates $1.04 billion in revenue each year. The company earns $-110.86 million in net income (profit) each year or ($0.58) on an earnings per share basis.

How many employees does Alkermes have?

Alkermes employs 2,245 workers across the globe.

Does Alkermes have any subsidiaries?

The following companies are subsidiares of Alkermes: Rodin Therapeutics.

When was Alkermes founded?

Alkermes was founded in 1987.

What is Alkermes' official website?

The official website for Alkermes is www.alkermes.com.

Where are Alkermes' headquarters?

How can I contact Alkermes?

Alkermes' mailing address is 1 BURLINGTON ROAD CONNAUGHT HOUSE, DUBLIN L2, DUBLIN 4. The company can be reached via phone at (531) 772-8000, via email at [email protected], or via fax at 781-890-0524.


This page was last updated on 12/2/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.